Inhixa

Enoxaparin Sodium, the active ingredient in Inhixa, is a low molecular weight heparin presented as a sterile solution for subcutaneous, intravenous and haemodialysis use. It is employed to prevent and treat thromboembolic conditions in adult patients. GNH USA supplies Inhixa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Enoxaparin Sodium is used across several thromboembolic pathways to prevent and treat clot formation. - Deep vein thrombosis prophylaxis: reduces the risk of postoperative clot formation in surgical patients. - Acute deep vein thrombosis treatment: facilitates clot resolution and prevents extension. - Pulmonary embolism treatment: helps dissolve emboli and limits recurrence. - Hemodialysis circuit anticoagulation: maintains patency of extracorporeal circuits during dialysis sessions.

Enoxaparin Sodium may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site bruising or pain - Minor bleeding (e.g., gum or nosebleeds) - Nausea or vomiting - Headache - Fever or chills - Elevated liver enzymes

Serious or Rare Side Effects: - Major hemorrhage (intracranial, gastrointestinal) - Heparin‑induced thrombocytopenia (HIT) - Spinal or epidural hematoma - Severe allergic reactions (anaphylaxis) - Skin necrosis at injection site - Thrombosis despite therapy

When using Enoxaparin Sodium, clinicians should observe several safety measures. - Assess renal function: dose adjustment may be required in severe impairment. - Monitor platelet count: watch for sudden drops indicating HIT. - Evaluate bleeding risk: avoid in patients with active major bleeding. - Use caution with neuraxial procedures: consider timing to prevent spinal hematoma. - Review concomitant medications: anticoagulants and antiplatelet agents increase bleed risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin Sodium interacts with several drug classes that can modify its anticoagulant effect.

Major Interactions (Avoid): - Other anticoagulants (warfarin, direct oral anticoagulants) - Antiplatelet agents (aspirin, clopidogrel) - Thrombolytic therapy (alteplase) - Non‑steroidal anti‑inflammatory drugs (NSAIDs) - Neuraxial anesthesia or spinal puncture

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., vancomycin, quinolones) - ACE inhibitors or ARBs - Diuretics - Corticosteroids - Hormonal therapies (estrogen‑containing products)